Business
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022\nCanada NewsWire\nMONTREAL, Jan. 30, 2023\n\n\n\nRecord quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21Record revenues in 2022 of $27.7 million, up 105% over 2021Record revenues forecasted in Q1-23Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion of Respiratory Business Unit to include allergy following the addition of ALLERJECT®In excess of $60 million raised in financings in 2022MONTREAL, Jan. 30, 2023 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a fast-growing Canadian pharmaceutical company, today reported its financial results for the fourth quarter and year-ended October 31, 2022.\n\n \n \n \n \n \n \n\n \nFourth quarter and year-end 2022 Results Highlights:Record quarterly revenues of $12.7 million in Q4-22, compared to $3.4 million in Q4-21, up 274%Record annual revenues of $27.7 million for 2022, compared to $13.6 million in 2021, up 105%Record adjusted gross profit of $3.6 million in Q4-22 compared to $0.9 million in Q4-2021, up 320%Record annual adjusted gross profit for 2022 of $9.4 million compared to $4.5 million in 2021, up 109%Q4-22 net loss of $9.3 million compared to $7.7 million in Q4 20212022 net loss of $25.7 million compared to 14.2 million in 2021Q4-22 adjusted EBITDA loss of $2.9 million compared to $5.5 million in Q4-212022 adjusted EBITDA loss of $14.5 million compared to 8.6 million in 2021Cash and liquidities of $22.5 million at October 31, 2022\"2022 saw Valeo take a major step forward in becoming a leading Canadian owned pharmaceutical company. We generated record annual revenues, doubling our 2021 performance, and expanded our product portfolio by acquiring rights to three growth assets XIIDRA, SIMBRINZA and ALLERJECT\", said Steve Saviuk, C...